# A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

> **NCT01056510** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 357 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** bendamustine
- **DRUG:** chlorambucil
- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT01056510
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01056510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01056510, "A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01056510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*